Sam Abdelghany, PharmD, BCOP

ROSE DRUG

PO BOX 793

Articles

Carflizomib: A second-generation proteasome inhibitor for the treatment of myeloma

August 01, 2012

The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.